Int J Med Sci 2013; 10(3):230-234. doi:10.7150/ijms.5278 This issue Cite
Research Paper
Department of Surgical Oncology the First Affiliated Hospital, Xi'an Jiaotong University College of Medicine, Xi'an, Shaanxi 710061, China.
Background. Analysis of aberrant hypermethylation in stool DNA might provide a novel strategy for noninvasive detection of colorectal cancer.
Aims. To explore the feasibility of detecting hypermethylation in Spastic paraplegia-20 promoter as a stool-based DNA marker for detection of colorectal cancer.
Methods. We collected 96 tissue and stool samples from patients with colorectal cancer and 30 stool samples healthy individuals.
Results. Hypermethylated Spastic paraplegia-20 occurs in 85.4% (82/96) of patients with colorectal cancer in the tissue samples. In the stool samples, the results indicate 80.2% (77/96) sensitivity and 100% (30/30) specificity of the test for detecting colorectal cancer by using the stool samples as a noninvasive method.
Conclusions. The study reveals that hypermethylation in Spastic paraplegia-20 promoter is a highly specific and sensitive biomarker for screening colorectal cancer in stool samples as a noninvasive method.
Keywords: Colorectal cancer, Screening, SPG20, Stool DNA, Hypermethylation, Biomarker.